Navigation Links
Kantar Health to Highlight Strategies for Accessing U.S. and EU Markets for Japan Pharma
Date:10/27/2013

New York NY (PRWEB) October 28, 2013

Kantar Health, a leading global healthcare consulting firm, and Synix will host a seminar, “The Keys to Market Access Success in the U.S. and European Markets,” on November 14 in Tokyo.

Changes in the healthcare system in the U.S. and Europe have a significant impact on the process of introducing new pharmaceutical agents, particularly high-cost specialty drugs such as oncolytics, to these markets. The importance of evaluating benefit assessments from the viewpoint of various stakeholders, such as patients, physicians and insurers, is rapidly rising. This seminar ? led by Gordon Gochenauer, Director, Commercial Planning (U.S.), and Andrew Miniuks, Senior Director, Commercial Planning (Europe) ? will cover:

  • U.S. and European Healthcare Systems: Do patients have access to the needed treatments and medications?
  • Pricing and Reimbursement: Will the drugs be reimbursed by insurance?
  • Stakeholder Relationships: How should pharmaceutical companies build relationships with stakeholders?
  • Case Studies in Oncology: Recent pricing, reimbursement and coverage decisions that highlight similarities and differences between the U.S. and Europe

The seminar will begin at 1 pm. Visit Synix’s website to register for this event (http://www.synix.co.jp/assessment/seminar/20131114/detail.html) or contact Gen Okamoto at market.assessment(at)synix(dot)co(dot)jp for more information.

About Kantar Health
Kantar Health is a leading global healthcare consulting firm and trusted advisor to many pharmaceutical, biotech, and medical device and diagnostic companies worldwide. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and brand and marketing expertise to help clients evaluate opportunities, launch products and maintain brand and market leadership.

Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Its 700+ healthcare industry specialists work across the product lifecycle, from preclinical development to launch, acting as catalysts to successful decision-making in life sciences and helping clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. For more information, please visit http://www.kantarhealth.com.

Read the full story at http://www.prweb.com/releases/2013/10/prweb11270269.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Kantar Health to Highlight Role of Patient-Reported Outcomes in Russia
2. New Kantar Health Data Show Number of Newly Diagnosed Breast Cancer Patients in China Will Surpass U.S. by 2015
3. Biologic Treatment of Rheumatoid Arthritis Is Low in Brazil, According to Kantar Health Research
4. Treatment Rates of Prevalent Chronic Conditions Are Low in Brazil, According to Kantar Health Research
5. Kantar Health Americas CEO Mike Kelly Named to PharmaVOICE 100 for 2013
6. Kantar Health Launches CancerMPact Biomarker Analysis
7. Insulin Pump Therapy Provides Better Glycemic Control Among Type 1 Diabetics, According to Kantar Health Research
8. Two in Three Cancer Patients are Non-Adherent with Their Medications, According to Kantar Health Research
9. Kantar Health to Present at PBIRG Annual General Meeting
10. AACR honors Hagop Kantarjian for outstanding clinical research
11. Kantar Health to Participate in CIO Summit of America Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: